AML represents a disease that develops from the uncontrolled growth and survival of undifferentiated leukemia stem cells. These stem cells are particularly dependent for survival upon the MCL-1 ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have ...

and cell death. Abnormalities in tyrosine kinases are common in AML, and constitute an attractive therapeutic target. An example is given by the balanced chromosomal translocations (TEL-Abl ...

Syndax Pharmaceuticals has announced that its Phase II trial of revumenib achieved its primary endpoint in certain patients with relapsed or refractory acute myeloid leukaemia (AML). Despite this ...

Increased mixed chimerism, as detected by AlloHeme, could predict post-transplant relapse “with a high degree of accuracy,” said Monzr M. Al Malki, MD.

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious ...

The researchers can identify infected mice that develop leukemia, isolate the white blood cells and ... in clinical samples from patients with AML and myelodysplastic syndromes.